Oxytocin
Oxytocin (9-amino-acid neuropeptide; Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 with Cys-Cys disulfide bridge)
Endogenous neuropeptide produced by the hypothalamus, released by the posterior pituitary. Two distinct product forms:\n\n1. Pitocin / Syntocinon (FDA-approved, NDA 018261): IV/IM injectable for labor induction and postpartum hemorrhage management. Clinical/hospital use only.\n\n2. Compounded intranasal oxytocin: off-label use for social bonding, anxiety, autism, PTSD, sexual function. Available from compounding pharmacies (Empower Pharmacy, Harbor Compounding) with prescription. NOT FDA-approved for any psychiatric or behavioral indication. (Syntocinon nasal spray was withdrawn from US years ago.)\n\nThis entry primarily covers the intranasal off-label biohacker use case; the IV form is clinical-administration only. Note: replication crisis in oxytocin behavioral research: many early findings have not robustly replicated; should not be presented as well-established treatment.
At a glance
- Half-life
- ~3 min Plasma half-life: ~3-5 minutes (IV), ~15-20 minutes (intranasal). CNS effect duration after intranasal: 30-90 minutes effect window for behavioral studies. Intranasal bioavailability ~3%.
- Routes
- Nasal · SubQ · IV
- Evidence base
- 3 studies 2 human · 1 review
Mechanism
Oxytocin binds the oxytocin receptor (OXTR), a GPCR widely distributed in the CNS (amygdala, hypothalamus, hippocampus) and peripheral tissues (uterus, mammary gland).\n\nCNS effects (intranasal route): reduces amygdala fear response (anxiolytic); promotes social bonding, trust, empathy; reduces social anxiety; modulates HPA stress response; possible enhancement of gaze / facial recognition.\n\nPeripheral effects (IV/IM): uterine contraction (labor); milk let-down (mammary).\n\nNote: Peripheral oxytocin does not cross BBB efficiently. Intranasal route bypasses BBB via olfactory/trigeminal nerve transport. Replication concerns documented across the field.
Dosing
Any amounts shown here are reported from published studies only. 2 of 3 catalogued studies involved human subjects. COMPOUND does not publish its own dosing guidance.
Where a study reports an amount, it appears in that study's entry below, attributed to the source.
Published evidence
-
Human RCT 2008
Oxytocin increases gaze to the eye region of human faces
Intranasal oxytocin increased gaze to eyes; supports social cognition mechanism.
-
Human RCT 2005
Oxytocin increases trust in humans
24 IU intranasal oxytocin increased trust behavior in economic game; foundational behavioral oxytocin study sparking the modern field.
-
Review 2021
Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research
Comprehensive review of intranasal oxytocin research field; discusses BBB transport, dose-response challenges, replication issues. Important balanced perspective.
Reported side effects
- Mild nasal irritation
- Occasional Mild · Spray vehicle component, not oxytocin itself.
- Headache
- Occasional Mild · Reported in research subjects.
- Hyponatremia (with high IV doses, prolonged)
- Rare Serious · Antidiuretic effect at high doses; risk in IV labor induction. Not relevant for intranasal off-label use. FDA label.
- Uterine hyperstimulation (IV labor use only)
- Occasional Serious · IV-specific; not intranasal. FDA label.
Interactions
-
Kisspeptin-10 Synergy
Both modulate sexual / social neuroendocrine function. No formal interaction data.
-
PT-141 Synergy
Both target sexual function via distinct mechanisms (PT-141 = MC4R; oxytocin = OXTR). Theoretical additive sexual response.
Reconstitution and storage
Compounded nasal spray: pre-prepared by pharmacy at specified IU per spray. Powder form (research): reconstitute carefully. Oxytocin requires specific buffer (pH 4.5-6.5) for stability.
Compounded nasal spray: refrigerated 2-8°C; use within 30 days typically. Pitocin vials: refrigerated. Oxytocin is sensitive to heat and light. Protect from sunlight.